European medicinal cannabis powerhouse Curaleaf International has launched four branded flower strains in Australia to be distributed by Canngea, with more products to follow.
The firm said the move marked its expansion into “one of the world’s fastest-growing medical cannabis markets” and the beginning of a bigger presence in Down Under.
“Over the coming months, patients and healthcare professionals in Australia can look forward to a broader portfolio and further innovative solutions… including precision-dosed inhalation formats and popular strains already widely prescribed across the UK, Germany, and other key European markets,” it added.
Head of Curaleaf International Juan Martinez described the move as “a significant milestone in our global strategy to expand access to high-quality, evidence-backed cannabis medicines”.
“We’re committed to supporting Australian patients and healthcare professionals with reliable, consistent products and the backing of one of the industry’s most advanced supply chains,” he said.
Chairman and CEO Boris Jordan added: “Australia is an exciting and rapidly evolving market, expected to surpass $1 billion in annual sales next year, and this launch is a positive step forward in our strategy to extend our position as the global leader in cannabis.
“We’re bringing a proven portfolio and a strong track record of innovation, with more to come.”
Curaleaf International’s network includes a clinic, pharmacy, and laboratory in the UK, cultivation and EU-GMP processing facilities in Portugal, an EU-GMP processing, quality assurance and research site in Spain, Four20 Pharma – a wholesaler and distributor in Germany, a Polish wholesaler and clinic and the EU-GMP producer Northern Green Canada.